51846 Federal Register / Vol. 82, No. 215 / Wednesday, November 8, 2017 / Notices 

Dated: November 3, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–24308 Filed 11–7–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2013–D–0575] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Guidance for 

Industry on Expedited Programs for 

Serious Conditions—Drugs and 

Biologics 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed revision of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on the information 

collection in the guidance for industry 

‘‘Expedited Programs for Serious 

Conditions—Drugs and Biologics.’’ 

DATES: Submit either electronic or 

written comments on the collection of 

information by January 8, 2018. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before January 8, 

2018. The https://www.regulations.gov 

electronic filing system will accept 

comments until midnight Eastern Time 

at the end of January 8, 2018. Comments 

received by mail/hand delivery/courier 

(for written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2013–D–0575 for ‘‘Guidance for 

Industry on Expedited Programs for 

Serious Conditions—Drugs and 

Biologics.’’ Received comments, those 

filed in a timely manner (see 

ADDRESSES), will be placed in the docket 

and, except for those submitted as 

‘‘Confidential Submissions,’’ publicly 

viewable at https://www.regulations.gov 

or at the Dockets Management Staff 

between 9 a.m. and 4 p.m., Monday 

through Friday. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://www.gpo.gov

/fdsys/pkg/FR-2015-09-18/pdf/2015-

23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852. 

FOR FURTHER INFORMATION CONTACT: 

Domini Bean, Office of Operations, 

Food and Drug Administration, Three 

White Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–5733, PRAStaff@fda.

hhs.gov. 

SUPPLEMENTARY INFORMATION:

Guidance for Industry on Expedited 

Programs for Serious Conditions— 

Drugs and Biologics 

OMB Control Number 0910–0765— 

Revision 

This information collection supports 

the previous captioned Agency 

guidance. The guidance provides a 

single resource for information on 

FDA’s policies and procedures related 

to the following expedited programs for 

serious conditions: (1) Fast track 

designation, (2) breakthrough therapy 

designation, (3) accelerated approval, 

and (4) priority review designation. The 

guidance describes threshold criteria 

generally applicable to expedited 

programs, including what is meant by 

serious condition, unmet medical need, 

and available therapy. The guidance 

addresses the applicability of expedited 

programs to rare diseases, clarification 

on available therapy, and additional 

detail on possible flexibility in 

manufacturing and product quality. The 

guidance also clarifies the qualifying 

criteria for breakthrough therapy 


ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 215 / Wednesday, November 8, 2017 / Notices 51847 

designation and provides examples of 

surrogate endpoints and intermediate 

clinical endpoints used to support 

accelerated approval. 

The information collection resulting 

from requests for priority review 

designation and breakthrough therapy 

designation is set forth in rows 1 and 2 

of table 1 and is approved by the Office 

of Management and Budget (OMB) 

under control number 0910–0765. The 

information collection resulting from 

requests for accelerated approval is 

approved by OMB under control 

numbers 0910–0001 and 0910–0338. 

The provisions of the guidance 

relating to fast track development and 

other issues such as serious condition 

and unmet medical need replace the 

guidance entitled ‘‘Fast Track Drug 

Development Programs—Designation, 

Development, and Application Review.’’ 

Consequently, the information 

collection resulting from the guidance 

‘‘Fast Track Drug Development 

Programs—Designation, Development, 

and Application Review’’ (OMB control 

number 0910–0389) is now being 

incorporated into OMB control number 

0910–0765 (guidance for industry 

‘‘Expedited Programs for Serious 

Conditions—Drugs and Biologics’’). 

A sponsor or applicant who seeks fast 

track designation is required to submit 

a request to the Agency showing that the 

drug product: (1) Is intended for a 

serious or life-threatening condition and 

(2) has the potential to address an 

unmet medical need. The Agency 

expects that most information to 

support a designation request will have 

been gathered under existing 

requirements for preparing an 

investigational new drug (IND), new 

drug application (NDA), or biologic 

license application (BLA). If such 

information has already been submitted 

to the Agency, the information may be 

summarized in the fast track designation 

request. A designation request should 

include, where applicable, additional 

information not specified elsewhere by 

statute or regulation. For example, 

additional information may be needed 

to show that a product has the potential 

to address an unmet medical need 

where an approved therapy exists for 

the serious or life-threatening condition 

to be treated. Such information may 

include clinical data, published reports, 

summaries of data and reports, and a list 

of references. The amount of 

information and discussion in a 

designation request need not be 

voluminous, but it should be sufficient 

to permit a reviewer to assess whether 

the criteria for fast track designation 

have been met. 

After the Agency makes a fast track 

designation, a sponsor or applicant may 

submit a premeeting package that may 

include additional information 

supporting a request to participate in 

certain fast track programs. The 

premeeting package serves as 

background information for the meeting 

and should support the intended 

objectives of the meeting. As with the 

request for fast track designation, the 

Agency expects that most sponsors or 

applicants will have gathered such 

information to meet existing 

requirements for preparing an IND, 

NDA, or BLA. These may include 

descriptions of clinical safety and 

efficacy trials not conducted under an 

IND (e.g., foreign studies) and 

information to support a request for 

accelerated approval. If such 

information has already been submitted 

to FDA, the information may be 

summarized in the premeeting package. 

The Agency estimates the total annual 

number of respondents submitting 

requests for fast track designation is 

approximately 140, and the number of 

requests received is approximately 187 

annually. FDA estimates that the 

number of hours needed to prepare a 

request for fast track designation is 

approximately 60 hours per request 

(row 3 in table 1). 

Of the requests for fast track 

designation made per year, the Agency 

granted approximately 132 requests 

from 107 respondents, and for each of 

these granted requests, a premeeting 

package was submitted to the Agency. 

FDA estimates that the preparation 

hours are approximately 100 hours per 

premeeting package (row 4 in table 1). 

The guidance also refers to previously 

approved collections of information 

found in FDA regulations. The 

collections of information in 21 CFR 

202.1 and 21 CFR parts 314, and 601, 

and sections 505(a), 506(a)(1), 735, and 

736 of the Federal Food, Drug, and 

Cosmetic Act (21 U.S.C. 355(a), 

356(a)(1), 379(g), and 379(h)) have been 

approved under OMB control numbers 

0910–0686, 0910–0001, 0910–0338, 

0910–0014, and 0910–0297. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

Guidance for Industry: Expedited Programs for Serious 

Conditions—Drugs and Biologics 

Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

response 

Total hours 

Priority review designation request ...................................... 48 1.7 82 30 2,400 

Breakthrough therapy designation request .......................... 87 1.29 113 70 7,910 

Fast track designation request ............................................ 140 1.33 187 60 11,220 

Fast track premeeting packages ......................................... 107 1.23 132 100 13,200 

Total .............................................................................. ........................ ........................ ........................ ........................ 34,730 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

The data pertaining to fast track 

designation (last two rows of table 1) 

has changed since the last OMB 

approval. 

Dated: November 2, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–24296 Filed 11–7–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–D–6100] 

Intent To Review an Analysis Data 

Reviewer’s Guide; Notice of 

Availability, Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability; request 

for comments. 

SUMMARY: The Food and Drug 

Administration (FDA), Center for Drug 

Evaluation and Research (CDER), is 

establishing a public docket to collect 

comments related to a proposed 

Analysis Data Reviewer’s Guide (ADRG) 

template. As part of FDA’s ongoing 

collaboration with the Pharmaceutical 

Users Software Exchange (PhUSE), an 


ethrower on DSK3G9T082PROD with NOTICES